Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Cadence Pharmaceuticals, Inc. Stockholders

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (NASDAQ: CADX) concerning the proposed acquisition of the Company by Mallinckrodt plc (“Mallinckrodt”) (NYSE: MNK). Under the terms of the definitive merger agreement, Cadence stockholders will receive $14.00 in cash for each share of Cadence owned, valuing the transaction at approximately $1.3 billion on a fully diluted basis.